Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds

a technology of pyridine-1-oxide and process, which is applied in the direction of organic chemistry, chemistry apparatus and processes, organic racemisation, etc., can solve the problems of unsatisfactory yield of this process, and achieve the effects of high purity, good application prospects, and good application prospects

Inactive Publication Date: 2004-01-08
KEMPHARM DENMARK AS
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] The advantage of the invention is that, by the use of the compound of formula (I) of the invention as intermediate, it makes possible the production of highly pure N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridin-e-1-oxide-3-carboximidoyl chloride, which has valuable biological effects. Contrary to the process described in WO 00 / 50403 mentioned in the introduction, in which this compound is prepared by the oxidation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride, in this current process the appearance of the products of competitive reactions need not be taken into account. By the process of the invention, the base form of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-p-yridine-1-oxid-3-carboximidoyl chloride is obtained in high purity. Up to this point, this was only possible by lengthy purification, or by liberation of the base from the maleate salt.
[0019] A further advantage of the invention is that the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine of the invention may be produced by the merge of the steps described above and illustrated in the following examples in greater detail, without the isolation and / or purification of each intermediate product, still obtaining satisfactory purity. This way, the production of the intermediate N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-c-arboxamidine becomes possible in the circumstances of pharmaceutical production, which makes possible the industrial production of the biologically effective N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1--oxide-3-carboximidoyl chloride.BEST MODE OF CARRYING OUT THE INVENTION

Problems solved by technology

The yield of this process, however, is not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0021] The Preparation of 3-cyano-pyridine-1-oxide (Compound of Formula II)

[0022] 86 g (0.378 mol) of 76% m-chloro perbenzoic acid is dissolved in 730 ml of dichloro-methane at 20-25.degree. C., and 220 ml of the solution of 38.3 g (0.378 mol) of 3-cyano-pyridine in dichloro-methane is added at 20-28.degree. C. The reaction mixture is stirred at 20-24.degree. C. for 24 hours. At the end of the reaction, the solvent is evaporated. The evaporation residue is digerated in 430 ml of methyl terc-butyl ether, the precipitate is filtered, washed and dried. 59 g of raw product is obtained.

[0023] By recrystallizing the raw product twice from hot ethanol, 36.6 g (80%) of pure 3-cyano-pyridine-1-oxide is obtained, which melts at 174-176.5.degree. C. (literature: 174-175.degree. C.; J. Chem. Soc. 3680 (1959)).

example 2

[0024] The Preparation of 3-pyridine-amidoxim-1-oxide (Compound of Formula III)

[0025] 25.41 g (0.366 mol) of hydroxylamine hydrochloride and 36.6 g (0.305 mol) of 3-cyano-pyridine-1-oxide are dissolved in 540 ml of water, then 30.72 g (0.366 mol) of sodium-hydrogen carbonate is added in small portions. The reaction mixture is stirred for 2 hours at 20-25.degree. C. The suspension is filtered, the precipitate is washed with water, dried, and recrystallized from a 9:1 mixture of methanol and water. The precipitate separating on cooling is filtered, washed and dried. 37.3 g (80%) of the title compound is obtained, which melts at 212-215.degree. C. while decomposing.

[0026] IR: .nu. (KBr, cm.sup.-1): 3407, 3337, 2840, 1660, 1470, 1429, 1397, 1227, 947, 925, 808, 792.

example 3

[0027] a) The Preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyri-dine-1-oxide 3-carboxamidine (Compound of Formula I)

[0028] 13.5 g (0.34 mol) of sodium-hydroxide is dissolved in 35 ml of water, and the solution is cooled to 10.degree. C. 60.75 g (0.34 mol) of 2-hydroxy-4-azoniaspiro[3,5]nonane chloride is added, and the reaction mixture is stirred for 40 minutes at 5-10.degree. C. 540 ml of ethanol and 40.5 g (0.26 mol) 3-pyridine-amidoxim-1-oxide are added. The reaction mixture is heated for 2 hours under a reflux condenser. The solution is cooled, the separated sodium chloride is filtered, washed with 100 ml of ethanol, and then the solvent is evaporated off. The evaporation residue is digerated with diethyl-ether, the precipitate separated in the cooler is filtered, washed with ether, dried, and crystallized hot from isopropanol. 47.4 g (62%) of the title compound is obtained, which melts at 130-132.5.degree. C.

[0029] IR: .nu. (KBr, cm.sup.-1): 3397, 3189, 2928, 1647, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
optical purityaaaaaaaaaa
optical purityaaaaaaaaaa
optical purityaaaaaaaaaa
Login to View More

Abstract

The invention relates to N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers. (R)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and (S)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine. Furthermore, the invention relates to the preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxyimidoyl chloride, which may be used as an active ingredient of medicaments, and the preparation of the optically active enantiomers of this compound using the compounds of the invention as intermediate substances.

Description

[0001] The invention relates to a new pyridine-1-oxide-3-carboxamidine derivative, which may be used as intermediate in the production of the active ingredient of pharmaceutical products for the treatment of diabetic complications. Namely, the invention relates to the compound N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers, (R)-(-)-N-[2-hydroxy-3-(1-piperidin-yl)-propoxy]-pyridine-1-oxide-3-carboxamidine and (S)-(+)-N-[2-hydroxy-3-(-1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine. Furthermore, the invention relates to the preparation of N-[2-hydroxy-3-(1-piperidinyl)-pr-opoxy]-pyridine-1-oxide-3-carboximidoyl chloride, which may be used as an active ingredient of medicaments, and the preparation of the optically active enantiomers of this compound using the compounds of the invention as intermediate substances.BACKGROUD ART[0002] N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride, along wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07B57/00C07D213/89
CPCC07D213/89Y02P20/55C07D401/12
Inventor UROGDI, LASZLOCSAKAI, ZITA JEGESNEGRUBER, LAJOSOTVOS, LASZLOTOTHTOMOSKOZI, ISTVANSZAKACSNE SCHMIDT, ANIOREIDER, FERENCNESCHNEIDERNE BARLAY, MARIA
Owner KEMPHARM DENMARK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com